Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - Recursion Pharmaceuticals reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, representing an earnings surprise of -17.14% [1] - The company posted revenues of $19.22 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 33.71%, compared to revenues of $14.42 million a year ago [2] - Over the last four quarters, Recursion Pharmaceuticals has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Movement and Outlook - Shares of Recursion Pharmaceuticals have declined approximately 14.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.32 on revenues of $13.37 million, and for the current fiscal year, it is -$1.35 on revenues of $68.39 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Recursion Pharmaceuticals belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]